Edwardsiella tarda has been reported as the caus ative agent of edwardsiellosis in a variety of cultured fish such as Japanese eel Anguilla japonica, tilapia Oreochromis niloticus, red sea bream Pagrus major and Japanese flounder Paralichthys olivaceus. Vaccina tions against E. tarda have been performed in Japanese flounder with a variety of antigen preparations that are formalin-killed cells (FKC), extracellular products (ECP) or intracellular components (ICC). These data sug gested that clear protection was not observed in any immunization with FKC, ECP or ICC (Mekuchi et al., 1995) . The vaccination of Japanese eel was also investigated (Salati et al., 1983) . The vaccine against E. tarda, however, has not been commercialized yet.
We reported that E. tarda needs siderophore pro duction for its virulence (Igarashi et al., 2002) . A mutant with lowered siderophore productivity derived from a virulent strain might have potential as a live vaccine that is expected to confer excellent protection against edwardsiellosis.
We described here a vaccination trial Vaccination and measurement of antibody The SPM31 strain was used as a vaccine strain. Each 50 fish weighing about 42 g each were vaccinated intraperitoneally with the live or the formalin-killed cells at a dose of 0.1 mg/100 g (about one third of the LD50 value), and kept in 160 L plastic tanks, separately.
Half of the water in the tanks was changed everyday with dechlorinated municipal water.
In order to confirm the persistency of live SPM31 in the internal organs, the mutant was reisolated from the kidneys of 2 fish using LBc agar containing kanamycin at the 1st, 2nd3rd and 4th weeks of post-vaccination.
Blood samples were collected from 5 fish per group at the 1st, 2nd 3rd and 4th weeks of post-vaccination. The agglutinating titers of the sera were determined as antibody titers.
Challenge test
Protection against E. tarda was examined by injection of the parent strain FPC498 at 0.1 mg/100 g at the nd3rd and 4th weeks of post -vaccination . Non-vaccinated fish were also challenged as control fish. Bacteria were isolated from the kidney and liver of all dead fish, and the isolates were confirmed as E. tarda by an antiserum against E. tarda serotype A (Park et al., 1983) .
Results
Induction of a lowered siderophore productivity mutant
Only one strain from a total of more than 10,000 transductants was selected as a mutant with the lowered siderophore production.
Modified CAS assay showed that the mutant (SPM31) has an apparently lower production of siderophore than the original strain, although it shows a positive reaction compared with an avirulent strain SU138 (Fig. 1) . This mutant, as well as the original strain, was agglutinated against an antiserum against the E. tarda serotype A. Vaccination and determination of antibody titers Five fish died within 3 days following vaccination of tilapia with live E. tarda SPM31 by the peritoneal injection. SPM31 was reisolated from the dead fish, indicating that the fish died from edwardsiellosis. SPM31 was reisolated from the kidney of the live fish immunized with the live cells at the 1st and 2nd weeks of post-vaccination, while not at the 3rd and 4th weeks of post-vaccination.
Antibodies were induced by injection with both the live and the formalin-killed cells. However, the live cells enhanced higher antibody response in tilapia than the formalin-killed cells (Fig. 2) . SPM31 is a mutant from FPC498; FPC498 is virulent; SU138 is avirulent. one were killed within 3 days. Any bacteria were not isolated from the kidney of all surviving fish at the 4th week of post-challenge.
Discussion
There are some investigations for live attenuated vaccines against fish bacterial diseases by Vibrio anguillarum (Norqvist et al., 1989) , Aeromonas hydrophila (Hernanz Moral et al., 1998) , Aeromonas salmonicida (Vaughan et al., 1993) , Edwardsiella ictaluri (Klesius and Shoemaker, 1999) and Renibacterium salmoninarum (Daly et al., 2001 ). All attempts resulted in satisfactory protection against infections. Against diseases caused by intracellular pathogens such as A. salmonicida, E. ictaluri and R. salmoninarum, because bacterin vaccines without adjuvants yielded inadequate protections (Hastings, 1988; Munro and Bruno, 1988; Plumb, 1988) , the application of live attenuated vaccines have been expected to be a new strategy to control the diseases.
Recently, a live E. ictaluri vaccine has been licensed, produced and marketed against enteric septi cemia of catfish in the US (Shoemaker et al., 2002) .
The trials of vaccination against edwardsiellosis have been performed in some fish. In Japanese eel, Salati et al. (1983) prepared three types of vaccines, for malin-killed cells, culture filtrate and lipopolysaccharide (LPS). All preparations stimulated the production of antibody, but the last one conferred significant protection against the experimental challenge, while the others failed. Mekuchi et al. (1995) reported the similar results in Japanese flounder, in which formalin-killed bacterin raised antibody titers without prominent protective immunity. These results suggest that antibody res ponses have little effect on preventing the infection of E. tarda. In the present study, we also showed positive antibody production and negative protection by the formalin-killed cells. On the other hand, the live attenu ated E. tarda mutant (SPM31) provided complete protec tion against the experimental challenge with the parent virulent strain FPC498. A live attenuated A. salmonicida vaccine was demonstrated to preferentially stimulate T cell responses relative to B-cell responses in rainbow trout Oncorhynchus mykiss (Marsden et al., 1996) , indi cating that live vaccines elicit strong cell-mediated immune responses.
E. tarda has been suggested to have an intracellular nature (Miyazaki and Kaige, 1985; lida et al., 1993; Rashid et al., 1997) . Activated cell mediated immunity must be required for the successful vaccination against edwardsiellosis.
At a preliminary experiment, injection of live cells of the parent strain FPC498 at a dose less than LD50 did not induce complete protection against the challenge (data not shown), suggesting that vaccination at a rela tively high dose of live E. tarda is needed for establishing completely protective immunity. From the result, we tried to construct attenuated mutants. Auxotrophic mutants, for example aroA mutant of A. hydrophila (Hernanz Moral et al., 1998) or A. salmonicida (Vaughan et al., 1993) , and purA mutant of E. ictaluri (Lawrence et al., 1997) , have been constructed in order to investigate the possibility of effective live-attenuated vaccines. Siderophore is possibly one of the virulence factors of E. tarda (Igarashi et al., 2002) , and Mathew et al. (2001) have produced an E. tarda mutant with less production of siderophore, in which the mutant had reduced viru lence in blue gourami Trichogaster trichopterus. So, in the present study, we tried to make siderophore-produc tive mutants using transposon Tn5. We obtained only a mutant with lower siderophore-productivity than the par ent strain from a total of more than 10,000 trans ductants.
This derivative was partially attenuated in tilapia with a LD50 value of about 16 times higher than the parent strain. The mutant was recoverable from the kidney for at least 2 weeks after inoculation. Vaughan et al. (1993) showed that an aromatic-dependent mutant of A. salmonicida persisted in the kidney of brown trout Salmo trutta for 12 days.
Replication of the mutant strains was expected in vivo. Persistency of live vac cines in the internal organs might be important to estab lish activated cell-mediated immunity. Assuming the importance of the prolonged existence of vaccines in hosts for cell-mediated immunity, repeated inoculations with formalin-killed cells are worthy to be investigated to provide protective immunity. Edwardsiellosis has become a serious disease problem in the aquaculture in Japan. Especially, in Japanese flounder and red sea bream cultures, this dis ease is responsible for severe economic losses. We used tilapia as an experimental fish in the present study. Another trial must be needed to apply the live attenuated E. tarda vaccine for Japanese flounder and red sea bream. Our attenuated strain SPM31 doesn't completely lose the virulence. On the vaccination, 5 out of 50 fish died after the injection with SPM31 at a dose less than LD50. Less virulent and safer strains for the live vaccines must be produced for further experiments .
